University of Alberta Hospital

Edmonton T6G2B7

5 studies enrolling now · 12 studies all time

What they study most

Acute Ischemic Stroke, Acute Myeloid Leukemia, Advanced Chronic Liver Disease, Angelman Syndrome, Aortic Valve Stenosis, Atrial Fibrillation, Brain Infarction, Cardiovascular Diseases, Cerebral Ischemia, Chronic Myelomonocytic Leukemia, Erythropoietic Protoporphyria (EPP), Heart Failure

Studies at this site

• A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) — Recruiting now
• A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections — Recruiting now
• REVEAL: A Phase 3 Study of ION582 in Angelman Syndrome — Recruiting now
• Observational Study of Adults and Adolescents With Erythropoietic Protoporphyria (EPP) and X-linked Porphyria (XLP) — Recruiting now
• A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose) — Enrolling by invitation
• Double-blind, Randomized, Placebo-controlled Study Evaluating Efficacy and Safety of IgPro20 in Post-COVID-19 POTS — Stopped early
• EdoxabaN foR IntraCranial Hemorrhage Survivors With Atrial Fibrillation (ENRICH-AF) — Running, not enrolling
• The ARIES HeartMate 3 Pump IDE Study — Completed
• Non-invasive Methods and Surgical Risk Stratification in Cirrhotics Undergoing Elective Extrahepatic Surgery — Status unconfirmed
• Comparison of a Rivaroxaban-based Strategy With an Antiplatelet-based Strategy Following Successful TAVR for the Prevention of Leaflet Thickening and Reduced Leaflet Motion as Evaluated by Four-dimensional, Volume-rendered Computed Tomography (4DCT) — Completed
• Efficacy and Safety Study of DP-b99 in Treating Acute Ischemic Stroke — Stopped early
• Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke — Stopped early